Novel bioelectric medicine company Pulse Biosciences, Inc. (PLSE) announced Friday the appointment of Paul LaViolette, current Co-Chairman of the Board, as Chief Executive Officer.
LaViolette has significant experience as a large-scale operator at global healthcare corporations as well as a leader to a diverse group of innovative medical technology startups as a venture investor and board member.
As a Managing Partner at SV Health Investors, LaViolette invested in numerous portfolio companies and remains active on the Board of Directors of certain SV Health Investors portfolio companies.
Before his investing career, he served in various executive capacities at Boston Scientific Corp. for 15 years, including as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International.
Prior to Boston Scientific, he also served as President, Cardiology, for CR Bard and various marketing roles at Kendall (Medtronic).
LaViolette is currently a director for Edwards Lifesciences and Chairman of the Innovation Advisory Board at Mass General Brigham.
Additionally, the Company announced today the grant of inducement awards of options to purchase a collective total of up to 138,800 shares of common stock to eleven other new employees of the Company.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.